Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BDX
stocks logo

BDX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
5.50B
+8.77%
3.431
-1.97%
5.89B
+8.3%
3.984
+4.56%
5.37B
+4%
3.299
-3.82%
Estimates Revision
The market is revising Downward the revenue expectations for Becton, Dickinson and Company (BDX) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by -22.36%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.95%
In Past 3 Month
Stock Price
Go Down
down Image
-22.36%
In Past 3 Month
12 Analyst Rating
up Image0
Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 206.40 USD with a low forecast of 172.00 USD and a high forecast of 261.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
8 Hold
0 Sell
Moderate Buy
up Image0
Current: 175.340
sliders
Low
172.00
Averages
206.40
High
261.00
up Image0
Current: 175.340
sliders
Low
172.00
Averages
206.40
High
261.00
Stifel
Rick Wise
Strong Buy
Maintains
$280 → $224
2025-05-02
Reason
Stifel
Rick Wise
Price Target
$280 → $224
2025-05-02
Maintains
Strong Buy
Reason
Stifel analyst Rick Wise lowered the firm's price target on Becton Dickinson to $224 from $280 and keeps a Buy rating on the shares. Q2 performance and FY25 guidance were both "more disappointing and more complicated than anticipated," the analyst tells investors. Both the Q2 underperformance and now-higher China pressures are factors in the firm's revised estimates and price target, the analyst indicated.
Piper Sandler
Jason Bednar
Buy
to
Hold
Downgrades
$260 → $185
2025-05-02
Reason
Piper Sandler
Jason Bednar
Price Target
$260 → $185
2025-05-02
Downgrades
Buy
to
Hold
Reason
Piper Sandler analyst Jason Bednar downgraded Becton Dickinson to Neutral from Overweight with a price target of $185, down from $260. The firm says its "patience has fully worn out" on the company's "checkered execution path" for organic revenue. Piper's confidence has eroded in management's demand forecasting ability. Becton's fiscal Q2 saw nearly every segment revenue line miss expectatoins on an organic growth basis, the analyst tells investors in a research note. Piper "can no longer justifiably defend" that the company's guidance is achievable.
William Blair
Brian Weinstein
Buy
to
Hold
Downgrades
n/a
2025-05-01
Reason
William Blair
Brian Weinstein
Price Target
n/a
2025-05-01
Downgrades
Buy
to
Hold
Reason
Piper Sandler
Jason Bednar
Buy
Maintains
$280 → $260
2025-04-23
Reason
Piper Sandler
Jason Bednar
Price Target
$280 → $260
2025-04-23
Maintains
Buy
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping, with Becton Dickinson (BDX) and Sotera Health (SHC) looking best positioned to respond favorably to upcoming reports when considering current sentiment/positioning.
Barclays
Travis Steed
Buy
Maintains
$279 → $261
2025-04-07
Reason
Barclays
Travis Steed
Price Target
$279 → $261
2025-04-07
Maintains
Buy
Reason
Barclays lowered the firm's price target on Becton Dickinson to $261 from $279 and keeps an Overweight rating on the shares. The firm updated its sum-of-the-parts analysis following reports that the company plans to separate its Bioscience and Diagnostics Solutions business. It cites a drop in peer multiples for the target cut.
Barclays
Travis Steed
Buy
Maintains
$278 → $279
2025-02-14
Reason
Barclays
Travis Steed
Price Target
$278 → $279
2025-02-14
Maintains
Buy
Reason
Barclays raised the firm's price target on Becton Dickinson to $279 from $278 and keeps an Overweight rating on the shares. The firm says its updated sum-of-the-parts valuation analysis suggests 19% upside to Becton from current levels, based on an updated model estimates and several changes to assumptions.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Becton Dickinson and Co (BDX.N) is 12.27, compared to its 5-year average forward P/E of 19.71. For a more detailed relative valuation and DCF analysis to assess Becton Dickinson and Co 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PE
19.71
Current PE
12.27
Overvalued PE
22.13
Undervalued PE
17.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average EV/EBITDA
15.49
Current EV/EBITDA
10.32
Overvalued EV/EBITDA
17.17
Undervalued EV/EBITDA
13.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
3.57
Current PS
2.15
Overvalued PS
3.92
Undervalued PS
3.21

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BDX News & Events

Events Timeline

(ET)
2025-05-01
06:37:34
Becton Dickinson cuts FY25 adjusted EPS view to $14.06-$14.34 from $14.30-$14.60
select
2025-05-01
06:34:06
Becton Dickinson reports Q2 adjusted EPS $3.35, consensus $3.28
select
2025-03-20 (ET)
2025-03-20
06:54:02
Becton Dickinson announces first patient treated in GalaFLEX trial
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.5
05-12Newsfilter
PinnedBD to Announce Financial Results for its Third Quarter of Fiscal 2025

  • Upcoming Financial Webcast: BD will host an audio webcast on August 7, 2025, at 8 a.m. ET to discuss its third-quarter financial results for fiscal year 2025 and provide updates on operations and strategy.

  • Company Overview: BD is a leading global medical technology company focused on improving health care through innovative technologies and solutions, with a commitment to enhancing safety and efficiency in clinical care delivery.

Preview
8.5
05:02 AMYahoo Finance
PinnedFirst Eagle Investment's Strategic Moves: Spotlight on Becton Dickinson & Co

  • First Eagle Investment's Portfolio Changes: In Q1 2025, First Eagle Investment added 16 new stocks, notably Carlisle Companies Inc, Dycom Industries Inc, and Murphy Oil Corp, while increasing stakes in 230 existing holdings, particularly Becton Dickinson & Co and Bio-Rad Laboratories Inc. The firm also exited 28 positions entirely, including Charles Schwab Corp and SPDR S&P 500 ETF Trust.

  • Investment Strategy Overview: First Eagle Investment focuses on a value-oriented approach with long-term performance goals, utilizing rigorous fundamental analysis and direct engagement with company management to identify investment opportunities across various industries.

Preview
9.0
05-07Benzinga
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

  • FDA's New Inspection Policy: The FDA plans to expand unannounced inspections of foreign manufacturing facilities for food and medical products, aiming to ensure equal regulatory oversight as domestic companies, following concerns about advanced notice given to foreign firms.

  • Investment in U.S. Manufacturing: In response to potential tariffs on imported medicines, several pharmaceutical companies have announced significant investments in U.S. manufacturing capacity, with plans totaling over $200 billion from major firms like Johnson & Johnson, Novartis, and Bristol-Myers Squibb over the next five years.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Becton Dickinson and Co (BDX) stock price today?

The current price of BDX is 175.34 USD — it has increased 4.86 % in the last trading day.

arrow icon

What is Becton Dickinson and Co (BDX)'s business?

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

arrow icon

What is the price predicton of BDX Stock?

Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 206.40 USD with a low forecast of 172.00 USD and a high forecast of 261.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Becton Dickinson and Co (BDX)'s revenue for the last quarter?

Becton Dickinson and Co revenue for the last quarter amounts to 5.27B USD, increased 4.50 % YoY.

arrow icon

What is Becton Dickinson and Co (BDX)'s earnings per share (EPS) for the last quarter?

Becton Dickinson and Co. EPS for the last quarter amounts to 1.07 USD, decreased -42.16 % YoY.

arrow icon

What changes have occurred in the market's expectations for Becton Dickinson and Co (BDX)'s fundamentals?

The market is revising Downward the revenue expectations for Becton, Dickinson and Company (BDX) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by -22.36%.
arrow icon

How many employees does Becton Dickinson and Co (BDX). have?

Becton Dickinson and Co (BDX) has 73000 emplpoyees as of May 13 2025.

arrow icon

What is Becton Dickinson and Co (BDX) market cap?

Today BDX has the market capitalization of 50.25B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free